NeoSpine is now offering spinal cord stimulation (SCS) procedure(s) for the treatment of painful diabetic neuropathy (PDN). The technology is a newly approved nondrug treatment for PDN, and is the only SCS system with a specific indication to treat the condition.
More than 34 million people in the U.S. have diabetes, and it’s estimated that 20-25% of people with diabetes will develop PDN. The condition is associated with a wide range of symptoms including pain in the limbs described as burning, freezing, stabbing, shooting, hypersensitivity, or deep aching. Traditional treatment options for PDN include over-the-counter medications, prescription medications, physical therapy and injections, but for many people, these options are inadequate for long-term relief.
HFX for PDN is the only spinal cord stimulation system approved by the Food and Drug Administration (FDA) with a specific indication for PDN. HFX is a comprehensive solution that includes a Senza spinal cord stimulation system and support services for the treatment of chronic pain. HFX for PDN means that a patient has been implanted with a Senza System and programmed to include a frequency of 10 kHz.
The Senza device is implanted during a quick and minimally invasive procedure, and then begins delivering mild pulses at a high frequency directly to the spinal cord to stop pain signals from reaching the brain. In a recent study, 92% of patients reported high satisfaction with the therapy.
“People with PDN know it to be a cruel addition to the chronic disease they must fight every day,” said says Dr. Kathy Wang, Pain Management Specialist, NeoSpine. “HFX for PDN offers a new option to alleviate this agonizing and persistent sensation. There is no other therapy like this, and to offer it to people here at NeoSpine is an absolute privilege. I believe this can make a real difference for my patients with PDN.”
For important safety information regarding this new treatment, please visit here.
